Shopping Cart
- Remove All
 
Your shopping cart is currently empty
(S)-crizotinib (ent-crizotinib) (IC50 of 72 nM), an effective MTH1 (NUDT1) inhibitor, is the (S)-enantiomer of crizotinib.

| Pack Size | Price | Availability | Quantity | 
|---|---|---|---|
| 2 mg | $30 | In Stock | |
| 5 mg | $48 | In Stock | |
| 10 mg | $73 | In Stock | |
| 25 mg | $123 | In Stock | |
| 50 mg | $179 | In Stock | |
| 100 mg | $289 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $53 | In Stock | 
| Description | (S)-crizotinib (ent-crizotinib) (IC50 of 72 nM), an effective MTH1 (NUDT1) inhibitor, is the (S)-enantiomer of crizotinib.  | 
| Targets&IC50 |  MTH1:72 nM  | 
| In vitro | In the SW480 colorectal cancer model, daily oral administration of 50mg/kg (S)-Crizotinib effectively inhibits tumor growth.  | 
| In vivo | (S)-crizotinib activates DNA repair mechanisms in human colorectal cancer cells by inhibiting MTH1, thereby disrupting nucleotide pool homeostasis and further inducing an increase in DNA single-strand breaks.  | 
| Kinase Assay | MTH1 catalytic assay: Half-maximal inhibitory concentrations (IC50) are determined using a luminescence-based assay with some minor modifications. Briefly, serial dilutions of compounds are dissolved in assay buffer (100?mM Tris-acetate pH?7.5, 40?mM NaCl and 10?mM Mg(OAc)2 containing 0.005% Tween-20 and 2?mM dithiothreitol (DTT). Upon addition of MTH1 recombinant protein (final concentration 2?nM), plates are incubated on a plate shaker for 15?min at room temperature. After addition of the substrate dGTP (final concentration 100?μM), 8-oxo-dGTP (final concentration 13.2?μM), or 2-OH-dATP (final concentration 8.3?μM) the generation of pyrophosphate (PPi) as a result of nucleotide triphosphate hydrolysis by MTH1 is monitored over a time course of 15?min using the PPi Light Inorganic Pyrophosphate Assay kit. IC50 values are determined by fitting a dose-response curve to the data points using nonlinear regression analysis using the GraphPad Prism software.  | 
| Cell Research | One day before treatment, cells are seeded per well in six-well plates and incubated for 24 h. The next day DMSO (equal to highest amount of compound dilution, maximum 0.2%) or compounds in increasing concentrations were added and cells incubated at 37 °C, 5% CO2, for 7-10 days. After washing with PBS, cells are fixed with ice-cold methanol, stained with crystal violet solution (0.5% in 25% methanol) and left to dry overnight. For quantification of results, ultraviolet absorbance of crystal violet is determined at 595 nm following solubilisation by 70% ethanol. Data are analysed using nonlinear regression analysis using the GraphPad Prism software. (Only for Reference)  | 
| Synonyms | ent-crizotinib | 
| Molecular Weight | 450.34 | 
| Formula | C21H22Cl2FN5O | 
| Cas No. | 1374356-45-2 | 
| Smiles | C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl | 
| Relative Density. | 1.47 g/cm3 (Predicted) | 
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | 1eq. HCl: 9 mg/mL (20 mM)), Heating is recommended.  DMSO: 22.5 mg/mL (49.96 mM), Sonication is recommended.   | |||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.22 mM), Sonication is recommended.  Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||
Solution Preparation Table  | ||||||||||||||||||||||||||
1eq. HCl/DMSO 
  | ||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.